Investors in the drug sector must be aware of the regulatory challenges, competition and financial concerns associated with the research and development of new products. The Food and Drug Administration (FDA) regulates the drug sector very tightly, verifying that every drug is safe and effective before permitting it to reach the market. New drugs experience a lengthy testing period that may last 10 to 15 years before approval for sales. As a result of these challenges, drug manufacturers must be very resilient and financially stable in order to stay competitive in the marketplace. Investors should research the market thoroughly and calculate the risk-return tradeoff before investing in a drug sector stock.

The FDA uses incentives to encourage pharmaceutical companies to follow particular patterns. Generally speaking, pharmaceutical companies may have an easier time achieving approval for drugs that present the greatest overall benefit. The government encourages the development of orphan drugs, or drugs that lack potential for profitability because they target rare diseases. The FDA allows for a fast-track to approval. This policy benefits Americans waiting for drugs that target rare diseases. Drugs the government deems to be unsafe or ineffective will require further testing that the company may not be able to afford. Investors should consider the budget available to the company for research and development costs.

Smaller companies generally offer greater returns by allowing for ground-floor venture capital investment, but may not be able to withstand the length of time required for approval on their own. Large companies are more likely to have multiple drugs in their product lines and therefore are able to finance the path of new drugs through FDA approval. The profit potential of a successful, patented new drug is substantial and serves as strong motivation for many companies to see new drugs through the development process. To obtain new drugs for their product lines, large companies often acquire smaller companies. Small companies benefit from access to additional financial resources for the testing period. Mergers and acquisitions are common throughout the sector and happen largely in response to the regulatory environment experienced by creating new drugs. Mergers and acquisitions are common throughout the sector and happen largely in response to the regulatory environment experienced by creating new drugs.

Once off-patent, competitors often mimic successful drugs. These generic drugs offer the same efficacy at a substantial savings to consumers, making them a competition risk for pharmaceutical manufacturers. Other manufacturers are free to produce these drugs, so investors should expect popular treatments to become attractive targets for the production of generic brands. This in turn will lower the value of the original drug.

  1. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  2. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  3. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  4. What are the primary factors that drive share prices in the drugs sector?

    Learn about the primary factors that drive share prices in the drug sector. Creating and manufacturing drugs is a complex ... Read Answer >>
  5. What factors make the drug sector good for value investing?

    Discover what makes the drugs sector good for value investing. The perfect ingredient for value investors is to find undervalued ... Read Answer >>
  6. What level of return on equity is average for a company in the drugs sector?

    Find out more about the drugs sector, which industries are included in the sector and the average return on equity for companies ... Read Answer >>
Related Articles
  1. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  2. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  3. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  4. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  5. Insights

    The Industry Handbook: Pharma Industry

    Learn about the pharmaceutical industry and discover the forces that influence this highly profitable and dynamic sector.
  6. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
  7. Investing

    Senator Orders Investigation of Orphan Drug Abuse

    Iowa Senator Grassley ordered an inquiry into possible abuse of the Orphan Drug Act by drug makers.
  8. Insights

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
  9. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  10. Investing

    Drug Supply Chain May Be Driver of High Drug Prices

    Non-manufacturing stakeholders in the drug pricing system are the ones contributing to high prices.
  1. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  2. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  3. Abbreviated New Drug Submission (ANDS)

    A written request to Health Canada to obtain marketing approval ...
  4. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
  5. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
  6. Bioequivalence

    A similarity between two drugs meaning that they both have the ...
Hot Definitions
  1. Retirement Planning

    Retirement planning is the process of determining retirement income goals and the actions and decisions necessary to achieve ...
  2. Drawdown

    The peak-to-trough decline during a specific record period of an investment, fund or commodity. A drawdown is usually quoted ...
  3. Inverse Transaction

    A transaction that can cancel out a forward contract that has the same value date.
  4. Redemption

    The return of an investor's principal in a fixed income security, such as a preferred stock or bond; or the sale of units ...
  5. Solvency

    The ability of a company to meet its long-term financial obligations. Solvency is essential to staying in business, but a ...
  6. Dilution

    A reduction in the ownership percentage of a share of stock caused by the issuance of new stock. Dilution can also occur ...
Trading Center